PANIC
MCID: PNC025
MIFTS: 53

Panic Disorder (PANIC)

Categories: Mental diseases, Neuronal diseases, Respiratory diseases

Aliases & Classifications for Panic Disorder

MalaCards integrated aliases for Panic Disorder:

Name: Panic Disorder 12 75 37 55 43 44 15 17 72
Panic Anxiety Syndrome 12
Panic Disorder 1 72
Panic 55

Classifications:



External Ids:

Disease Ontology 12 DOID:594
KEGG 37 H01664
MeSH 44 D016584
NCIt 50 C34890
ICD10 33 F41.0
UMLS 72 C0030319 C1868649

Summaries for Panic Disorder

KEGG : 37
Panic disorder (PD) is a common type of anxiety disorder, characterized by unexpected and repeated panic attacks or fear of future panic attacks. It has a rapid onset and includes symptoms such as palpitations, chest pain, sweating and shaking. Some physical illnesses (e.g. asthma) commonly occur with panic disorder, and certain lifestyle factors (e.g. smoking) increase the risk for the disorder, but causal pathways are still unclear. In recent years, an association was found between panic symptoms and increased activity in the right frontal region of the brain. Genetic susceptibility factors also exist, but their exact nature and pathophysiological mechanisms remain unknown. Cognitive behavioural therapy (CBT) and several medications, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs) and benzodiazepines are effective for PD. Among these, SSRIs and SNRIs are considered to be first-line treatment agents because of their efficacy and favorable side effect profile.

MalaCards based summary : Panic Disorder, also known as panic anxiety syndrome, is related to panic disorder 1 and agoraphobia. An important gene associated with Panic Disorder is MIR22 (MicroRNA 22), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Valproic acid and Etoricoxib have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An anxiety disorder that is characterized by unexpected and repeated episodes of intense fear accompanied by physical symptoms that may include chest pain, heart palpitations, shortness of breath, dizziness, or abdominal distress.

MedlinePlus : 43 Panic disorder is a type of anxiety disorder. It causes panic attacks, which are sudden feelings of terror when there is no real danger. You may feel as if you are losing control. You may also have physical symptoms, such as Fast heartbeat Chest or stomach pain Breathing difficulty Weakness or dizziness Sweating Feeling hot or a cold chill Tingly or numb hands Panic attacks can happen anytime, anywhere, and without warning. You may live in fear of another attack and may avoid places where you have had an attack. For some people, fear takes over their lives and they cannot leave their homes. Panic disorder is more common in women than men. It usually starts when people are young adults. Sometimes it starts when a person is under a lot of stress. Most people get better with treatment. Therapy can show you how to recognize and change your thinking patterns before they lead to panic. Medicines can also help. NIH: National Institute of Mental Health

Wikipedia : 75 Panic disorder is an anxiety disorder characterized by reoccurring unexpected panic attacks. Panic... more...

Related Diseases for Panic Disorder

Diseases in the Panic Disorder family:

Panic Disorder 1 Panic Disorder 2
Panic Disorder 3

Diseases related to Panic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 439)
# Related Disease Score Top Affiliating Genes
1 panic disorder 1 35.5 PAND1 COMT
2 agoraphobia 32.5 SLC6A4 SLC6A2 PTK7 MAOA HTR1A CCKBR
3 obsessive-compulsive disorder 32.4 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
4 anxiety 32.2 TSPO TPH2 SLC6A4 PTK7 MAOA HTR3A
5 major depressive disorder 32.2 TPH2 SLC6A4 SLC6A2 MAOA HTR3A HTR2A
6 avoidant personality disorder 32.1 SLC6A4 MAOA
7 social phobia 32.0 SLC6A4 MAOA HTR3A HTR1A CCK
8 personality disorder 32.0 SLC6A4 MAOA HTR2A HTR1A COMT
9 depression 31.9 TPH2 SLC6A4 MAOA HTR2A HTR1A CRH
10 substance abuse 31.9 SLC6A4 MAOA COMT
11 dysthymic disorder 31.8 SLC6A4 MAOA HTR2A
12 phobia, specific 31.8 MAOA COMT
13 alexithymia 31.7 SLC6A4 HTR1A COMT
14 eating disorder 31.5 SLC6A4 CRH COMT CCK
15 irritable bowel syndrome 31.4 SLC6A4 HTR3A CRH CCK
16 mental depression 31.4 TPH2 SLC6A4 SLC6A2 MAOA HTR2A HTR1A
17 phobic disorder 31.4 SLC6A4 PTK7 MAOA HTR1A COMT
18 generalized anxiety disorder 31.4 TSPO SLC6A4 SLC6A2 MAOA HTR3A HTR2A
19 endogenous depression 31.3 SLC6A4 MAOA HTR2A HTR1A CRH
20 post-traumatic stress disorder 31.2 SLC6A4 MAOA HTR2A CRH COMT
21 constipation 31.1 SLC6A4 HTR3A CCK
22 mood disorder 31.0 TPH2 SLC6A4 SLC6A2 MAOA HTR2A HTR1A
23 bipolar i disorder 31.0 SLC6A4 HTR2A HTR1A COMT
24 bipolar disorder 31.0 SLC6A4 HTR2A HTR1A DAOA-AS1 COMT
25 bulimia nervosa 31.0 SLC6A4 HTR3A HTR2A COMT CCK
26 migraine with or without aura 1 31.0 SLC6A4 MAOA HTR3A HTR2A HTR1A COMT
27 tobacco addiction 30.9 SLC6A4 MAOA HTR2A COMT
28 borderline personality disorder 30.9 TPH2 SLC6A4 MAOA HTR2A HTR1A COMT
29 amnestic disorder 30.9 TSPO HTR3A HTR1A
30 alcohol dependence 30.8 TSPO TPH2 SLC6A4 MAOA HTR3A HTR2A
31 premature ejaculation 30.8 SLC6A4 HTR3A HTR1A
32 schizoaffective disorder 30.8 SLC6A4 HTR2A COMT
33 postpartum depression 30.8 SLC6A4 MAOA CRH COMT
34 dyspepsia 30.7 SLC6A4 HTR3A HTR1A CCKAR CCK
35 antisocial personality disorder 30.7 SLC6A4 MAOA COMT
36 conduct disorder 30.7 SLC6A4 MAOA COMT
37 gastrointestinal system disease 30.6 CRH CCKBR CCKAR CCK
38 psychotic disorder 30.6 SLC6A4 HTR3A HTR2A HTR1A COMT
39 atypical depressive disorder 30.6 SLC6A4 MAOA HTR2A CRH
40 fibromyalgia 30.6 TSPO SLC6A4 HTR3A HTR2A CRH COMT
41 anorexia nervosa 30.6 SLC6A4 HTR2A CRH COMT CCK
42 attention deficit-hyperactivity disorder 30.6 TPH2 SLC6A4 SLC6A2 MAOA HTR2A HTR1A
43 tardive dyskinesia 30.5 HTR2A COMT
44 cocaine abuse 30.5 SLC6A4 SLC6A2 HTR3A
45 paranoid schizophrenia 30.4 TPH2 SLC6A4 MAOA HTR2A COMT CCKAR
46 serotonin syndrome 30.3 SLC6A4 MAOA HTR3A HTR2A HTR1A
47 parkinson disease, late-onset 30.2 SLC6A4 MAOA HTR2A HTR1A COMT
48 central nervous system disease 30.0 SLC6A4 SLC6A2 HTR2A
49 sudden infant death syndrome 30.0 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
50 chronic fatigue syndrome 29.9 TPH2 SLC6A4 MAOA HTR2A HTR1A CRH

Graphical network of the top 20 diseases related to Panic Disorder:



Diseases related to Panic Disorder

Symptoms & Phenotypes for Panic Disorder

GenomeRNAi Phenotypes related to Panic Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Panic Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 CCKAR CCKBR COMT CRH HTR1A HTR2A
2 cardiovascular system MP:0005385 9.97 CCKBR COMT HTR1A MAOA PTK7 SLC6A2
3 homeostasis/metabolism MP:0005376 9.93 CCK CCKAR CCKBR COMT CRH HTR1A
4 endocrine/exocrine gland MP:0005379 9.91 CCK CCKAR CCKBR COMT CRH HTR2A
5 nervous system MP:0003631 9.73 CCK CCKAR CCKBR COMT CRH HTR1A
6 renal/urinary system MP:0005367 9.17 CCK CCKAR CCKBR COMT CRH HTR3A

Drugs & Therapeutics for Panic Disorder

Drugs for Panic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 251)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
2
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
3
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
4
Norepinephrine Approved Phase 4 51-41-2 439260
5
Propranolol Approved, Investigational Phase 4 525-66-6 4946
6
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
7
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
8
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
9
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
10
Clozapine Approved Phase 4 5786-21-0 2818
11
Ziprasidone Approved Phase 4 146939-27-7 60854
12
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
13
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
14
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
15
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
16
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
17
Promethazine Approved, Investigational Phase 4 60-87-7 4927
18
Suvorexant Approved, Investigational Phase 4 1030377-33-3
19
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
20
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
21
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
22
Sertraline Approved Phase 4 79617-96-2 68617
23
Alprazolam Approved, Illicit, Investigational Phase 4 28981-97-7 2118
24 Cyclooxygenase Inhibitors Phase 4
25 Cyclooxygenase 2 Inhibitors Phase 4
26 Anti-Inflammatory Agents, Non-Steroidal Phase 4
27 Antirheumatic Agents Phase 4
28 Neurotransmitter Agents Phase 4
29 Serotonin Uptake Inhibitors Phase 4
30 Antidepressive Agents Phase 4
31 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
32 Cytochrome P-450 Enzyme Inhibitors Phase 4
33 Neurotransmitter Uptake Inhibitors Phase 4
34 Psychotropic Drugs Phase 4
35 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
36 Peripheral Nervous System Agents Phase 4
37 Duloxetine Hydrochloride Phase 4
38 Antihypertensive Agents Phase 4
39 Adrenergic beta-Antagonists Phase 4
40 Adrenergic Antagonists Phase 4
41 Adrenergic Agents Phase 4
42 Anti-Arrhythmia Agents Phase 4
43 Quetiapine Fumarate Phase 4 111974-72-2
44 Antipsychotic Agents Phase 4
45 Serotonin 5-HT1 Receptor Agonists Phase 4
46 Serotonin Antagonists Phase 4
47 Serotonin 5-HT3 Receptor Antagonists Phase 4
48 Dopamine Antagonists Phase 4
49 Serotonin 5-HT2 Receptor Antagonists Phase 4
50 Dopamine D2 Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 349)
# Name Status NCT ID Phase Drugs
1 Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release Unknown status NCT00492414 Phase 4 Paroxetine CR
2 A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder. Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
3 Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures Unknown status NCT00755521 Phase 4 etoricoxib
4 A Randomized, Double-Blind, Multicenter Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder Completed NCT00677352 Phase 4 sertraline;Paroxetine
5 Phase 4 Study of Panic Disorder That Expresses to Change of Cerebral Glucose Metabolism After 12 Week of Paroxetine Treatment Completed NCT00767754 Phase 4 Paxil CR
6 The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder Completed NCT00438971 Phase 4 Duloxetine
7 Changes of Cerebral Glucose Metabolism Associated With the Fear Network Activity Before and After 12 Weeks of Escitalpram Treatment in Panic Disorder Completed NCT00767871 Phase 4 Lexapro
8 Randomized Controlled Trial of Escitalopram Versus Placebo for Patients With Irritable Bowel Syndrome and Panic Disorder Completed NCT01551225 Phase 4 Escitalopram
9 A Randomized, Controlled Trial on the Effects of Paroxetine Versus Placebo in Combination With Aerobic Exercise or Relaxation Training in the Treatment of Panic Disorder Completed NCT00540098 Phase 4 paroxetine + aerobic exercise;Paroxetine + relaxation;Placebo + aerobic exercise;Placebo + relaxation
10 The Effects of Treatment With Sertraline for Panic Disorder and/or Depression Driven Chest Pain and/or Palpitations in a Double Blind, Care as Usual and Placebo Controlled Study Completed NCT01114100 Phase 4 sertraline;placebo
11 An 8-week, Randomized, Double-Blind, Placebo-Controlled Trial of Seroquel SR Co-administration for SSRI-Resistant, Comorbid Panic Disorder Completed NCT00619892 Phase 4 quetiapine XR;placebo
12 A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder Completed NCT02395510 Phase 4 Vortioxetine
13 A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Current at Least Moderately Severe Anxiety and Lifetime Panic Disorder or Generalized Anxiety Disorder Completed NCT00167479 Phase 4 risperidone (Risperdal)
14 Aripiprazole for the Treatment of Refractory Anxiety: Impact on Clinical Outcomes, Resilience and Neuroendocrinologic Parameters Completed NCT00438386 Phase 4 Aripiprazole
15 Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment: a Clinical Randomized Trial Completed NCT00803400 Phase 4 Alprazolam;Alprazolam + Aerobic exercise
16 Combined Treatment With A Benzodiazepine (Clonazepam) And A Selective Serotonin Reuptake Inhibitor (Paroxetine) For Rapid Treatment Of Panic Disorder With Depression Completed NCT00031317 Phase 4 Paroxetine;Clozapine
17 A Multicenter, Randomized, Open-label, Parallel Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder Completed NCT00266409 Phase 4 Niravam;SSRI/SNRI
18 A Randomized Double-Blind Comparison of Sertraline With Early Alprazolam XR Co-Administration vs Sertraline/Placebo for Primary Care Panic Disorder Patients Completed NCT00198094 Phase 4 Sertraline and Alprazolam XR
19 Long-term, Open, Naturalistic, Randomized Clinical Trial With Clonazepam and Paroxetine in Panic Disorder With or Without Agoraphobia Completed NCT02852577 Phase 4 Clonazepam;Paroxetine
20 A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder Completed NCT01172652 Phase 4 Ziprasidone;Placebo
21 Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes Completed NCT00347269 Phase 4 Psychotropic medication optimization
22 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients (MOSAIC) Completed NCT01201967 Phase 4
23 A Randomized Controlled Trial of Cognitive Behavioural Therapy for Non-cardiac Chest Pain and Palpitations. Completed NCT00623454 Phase 4
24 Investigation of Genetic Predictors of the Response to SSRI Treatment Completed NCT03927950 Phase 4 escitalopram;bupropion
25 12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
26 Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
27 A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Immediate-Release Formulation of Quetiapine Fumarate as Potentiation of Selective Serotonin Reuptake Inhibitors, and Serotonin Norepinephrine Reuptake Inhibitors Treatment in Major Depression With Comorbid Anxiety Symptoms Completed NCT00229645 Phase 4 Quetiapine Fumarate (Seroquel®)
28 Single-Site, Double-Blind, Flexible-Dose, Placebo-Controlled Study of the Efficacy, Tolerability, & Safety of Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
29 Pharmacotherapy in Depression With Panic Spectrum Completed NCT00177996 Phase 4 sertraline hydrochloride
30 Cannabinoid Control of Fear Extinction Neural Circuits in Humans Completed NCT02472847 Phase 4 Dronabinol;Placebo
31 Psychophysiology of Delayed Extinction and Reconsolidation in Humans Completed NCT01631682 Phase 4 Propranolol;Mifepristone;Intranasal oxytocin
32 Comparative Effectiveness of Mindfulness-Based Stress Reduction and Pharmacotherapy for Anxiety Recruiting NCT03522844 Phase 4 Escitalopram
33 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Recruiting NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
34 Effects of Perampanel on Neurophysiology Test Perimeters Recruiting NCT03653741 Phase 4 Perampanel 6 MG
35 The Role of Orexin in Human Panic Disorder Active, not recruiting NCT02593682 Phase 4 suvorexant;placebo
36 Efficacy of Rapid-Acting NMDA Antagonist for Treatment of Adolescent Depression and Anxiety Disorders Active, not recruiting NCT02579928 Phase 4 Ketamine;Midazolam
37 A Pragmatic Randomized Comparator Trial of Eszopiclone and Brief Behavioral Therapy for Insomnia in CPAP Non Adherent Veterans With PTSD and Complex Insomnia Not yet recruiting NCT03937713 Phase 4 eszopiclone
38 An Open-Label Study to Assess the Safety and Tolerability of Xanax XR in the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks Terminated NCT00634790 Phase 4 alprazolam XR
39 A Randomized, Double-Blind, Placebo-Controlled Study of Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder Terminated NCT00635531 Phase 4 alprazolam XR
40 A Randomized, Double-Blind, Placebo-Controlled Study of Continuation Treatment With Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder Terminated NCT00635076 Phase 4 alprazolam XR
41 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
42 Mechanisms of CBT-Treatment Effects in Patients With Panic Disorder and Panic Disorder With Agoraphobia: The Role of Interoceptive Exposure Unknown status NCT01323556 Phase 2, Phase 3
43 A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder Completed NCT00038896 Phase 3 Venlafaxine ER
44 A Double-blind, Placebo-controlled, Parallel-group Comparison of Venlafaxine Extended-release Capsules and Paroxetine in Outpatients With Panic Disorder Completed NCT00044772 Phase 3 Venlafaxine ER
45 Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine. Completed NCT00195598 Phase 3 VENLAFAXINE;Paroxetine
46 Randomized Controlled Trial of Psychodynamic Psychotherapy vs. Applied Relaxation for Panic Disorder Completed NCT00128388 Phase 2, Phase 3
47 Treatment Refractory Panic Disorder Completed NCT00118417 Phase 2, Phase 3 Clonazepam;Sertraline
48 Internet- Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder in a Psychiatric Setting: A Randomized Equivalence Trial Completed NCT00845260 Phase 3
49 Dynamic Treatment vs. CBT for Panic Disorder Completed NCT00353470 Phase 3
50 Treatment of Panic Disorder: Long Term Strategies Completed NCT00000368 Phase 3 Paroxetine or other medication - algorithm used

Search NIH Clinical Center for Panic Disorder

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Alprazolam
Alprazolam
Citalopram
Clomipramine
Clomipramine
Clomipramine Hydrochloride
Clonazepam
Clonazepam
Desipramine
Diazepam
Escitalopram
Fluoxetine
Fluoxetine
Fluoxetine Hydrochloride
Fluvoxamine
Fluvoxamine Maleate
Imipramine
Imipramine
Imipramine Hydrochloride
Imipramine pamoate
Lorazepam
Maprotiline
Maprotiline Hydrochloride
Mirtazapine
Paroxetine
Paroxetine
Paroxetine Hydrochloride
Propranolol
Propranolol Hydrochloride
Sertraline
Sertraline
Sertraline Hydrochloride
Temazepam
Venlafaxine

Cochrane evidence based reviews: panic disorder

Genetic Tests for Panic Disorder

Anatomical Context for Panic Disorder

MalaCards organs/tissues related to Panic Disorder:

41
Brain, Heart, Testes, Amygdala, Cortex, Thyroid, Pituitary

Publications for Panic Disorder

Articles related to Panic Disorder:

(show top 50) (show all 8806)
# Title Authors PMID Year
1
The evaluation of metacognitive beliefs and emotion recognition in panic disorder and generalized anxiety disorder: effects on symptoms and comparison with healthy control. 38 17
31157577 2019
2
Emotion Regulation Strategies in Cognitive Behavioral Therapy for Panic Disorder. 38 17
31030881 2019
3
Meta-Analysis of Neuropsychological Studies in Panic Disorder Patients: Evidence of Impaired Performance during the Emotional Stroop Task. 38 17
30970364 2019
4
Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 are associated with panic disorder and regulate several anxiety candidate genes and related pathways. 38 88
21168126 2011
5
Platelet serotonin transporter function and heart rate variability in patients with panic disorder. 9 38
20358007 2010
6
Gene variations in the cholecystokinin system in patients with panic disorder. 9 38
20023595 2010
7
Association of a polyadenylation polymorphism in the serotonin transporter and panic disorder. 9 38
19969287 2010
8
The complex global pattern of genetic variation and linkage disequilibrium at catechol-O-methyltransferase. 9 38
18574484 2010
9
Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR). 9 38
18663369 2010
10
The symptomatic profile of panic disorder is shaped by the 5-HTTLPR polymorphism. 9 38
19683026 2009
11
Changes in CCK-4 induced panic after treatment with the GABA-reuptake inhibitor tiagabine are associated with an increase in 3alpha,5alpha-tetrahydrodeoxycorticosterone concentrations. 9 38
19501468 2009
12
CCK as a modulator of cardiovascular function. 9 38
19563885 2009
13
The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects. 9 38
19289240 2009
14
779 TC of CCK-1 intron 1 is associated with postprandial syndrome (PDS) in Japanese male subjects. 9 38
19760980 2009
15
Effects of experimentally induced panic attacks on neuroimmunological markers. 9 38
19023641 2009
16
Sympathetic activity relates to adenosine A(2A) receptor gene variation in blood-injury phobia. 9 38
18629431 2009
17
Impact of loudness dependency of auditory evoked potentials on the panic response to CCK-4. 9 38
18534623 2009
18
The association between serotonin-related gene polymorphisms and panic disorder. 9 38
18436425 2008
19
Association testing of panic disorder candidate genes using CCK-4 challenge in healthy volunteers. 9 38
18832011 2008
20
Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. 9 38
18384079 2008
21
Influence of the catechol-O-methyltransferase val158met genotype on amygdala and prefrontal cortex emotional processing in panic disorder. 9 38
18440204 2008
22
Platelet 18 kDa Translocator Protein density is reduced in depressed patients with adult separation anxiety. 9 38
18054208 2008
23
Lack of association between the serotonin transporter promoter polymorphism (5-HTTLPR) and personality traits in asymptomatic patients with panic disorder. 9 38
18164547 2008
24
Respiratory irregularity and stress hormones in panic disorder: exploring potential linkages. 9 38
17557312 2008
25
Lack of association between the Serotonin Transporter Promoter Polymorphism (5-HTTLPR) and Panic Disorder: a systematic review and meta-analysis. 9 38
17705872 2007
26
Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: reduction by a selective serotonin reuptake inhibitor. 9 38
17613943 2007
27
Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. 9 38
17318504 2007
28
Meta-analysis of COMT val158met in panic disorder: ethnic heterogeneity and gender specificity. 9 38
17357147 2007
29
Reduced serotonin-1A receptor binding in social anxiety disorder. 9 38
16979141 2007
30
Association study of tryptophan hydroxylase 2 gene polymorphisms in panic disorder. 9 38
17123728 2007
31
HPA axis activity in patients with panic disorder: review and synthesis of four studies. 9 38
16845643 2007
32
Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population. 9 38
16822601 2006
33
Association of the Val158Met catechol O-methyltransferase genetic polymorphism with panic disorder. 9 38
16525418 2006
34
The novel brain-specific tryptophan hydroxylase-2 gene in panic disorder. 9 38
16401665 2006
35
The neuronal noradrenaline transporter, anxiety and cardiovascular disease. 9 38
16785272 2006
36
Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety. 9 38
16600640 2006
37
Cholecystokinin hyperresponsiveness in functional dyspepsia. 9 38
16718754 2006
38
Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. 9 38
16541242 2006
39
Evidence that variation in the peripheral benzodiazepine receptor (PBR) gene influences susceptibility to panic disorder. 9 38
16511838 2006
40
Cell-specific repressor or enhancer activities of Deaf-1 at a serotonin 1A receptor gene polymorphism. 9 38
16467535 2006
41
Megestrol attenuates the hormonal response to CCK-4-induced panic attacks. 9 38
16470820 2006
42
Increased prevalence of functional gastrointestinal disorders in panic disorder: clinical and theoretical implications. 9 38
16273019 2005
43
Peripheral-type benzodiazepine receptor binding sites in platelets of patients with panic disorder associated to separation anxiety symptoms. 9 38
15830231 2005
44
Central cholecystokinin activity in irritable bowel syndrome, panic disorder, and healthy controls. 9 38
16046372 2005
45
Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects. 9 38
15939844 2005
46
The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder. 9 38
15953484 2005
47
Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. 9 38
15944741 2005
48
Association study of A2a adenosine receptor genetic polymorphism in panic disorder. 9 38
15774265 2005
49
Norepinephrine transporter (NET) promoter and 5'-UTR polymorphisms: association analysis in panic disorder. 9 38
15722184 2005
50
Epistatic interaction between the monoamine oxidase A and serotonin transporter genes in anorexia nervosa. 9 38
15523490 2005

Variations for Panic Disorder

Expression for Panic Disorder

Search GEO for disease gene expression data for Panic Disorder.

Pathways for Panic Disorder

GO Terms for Panic Disorder

Cellular components related to Panic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.7 SLC6A4 SLC6A2 PTK7 HTR3A HTR2A HTR1A
2 axon GO:0030424 9.56 HTR3A HTR2A COMT CCK
3 integral component of presynaptic membrane GO:0099056 9.13 SLC6A4 HTR3A HTR2A
4 integral component of postsynaptic membrane GO:0099055 8.8 SLC6A4 HTR3A HTR2A

Biological processes related to Panic Disorder according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.98 HTR2A HTR1A CRH CCKBR CCK
2 chemical synaptic transmission GO:0007268 9.77 SLC6A2 HTR3A HTR2A HTR1A CRH
3 memory GO:0007613 9.74 SLC6A4 HTR2A CCK
4 response to estrogen GO:0043627 9.67 TPH2 CRH COMT
5 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.63 HTR2A CCKBR CCKAR
6 response to drug GO:0042493 9.63 TSPO SLC6A4 SLC6A2 HTR2A CRH COMT
7 adrenal gland development GO:0030325 9.6 TSPO CRH
8 vasoconstriction GO:0042310 9.59 SLC6A4 HTR1A
9 neurotransmitter catabolic process GO:0042135 9.56 MAOA COMT
10 catecholamine metabolic process GO:0006584 9.55 MAOA COMT
11 positive regulation of mitochondrial depolarization GO:0051901 9.54 TSPO CCK
12 monoamine transport GO:0015844 9.52 SLC6A4 SLC6A2
13 behavior GO:0007610 9.51 HTR2A HTR1A
14 dopamine catabolic process GO:0042420 9.48 MAOA COMT
15 positive regulation of behavioral fear response GO:2000987 9.43 CRH CCK
16 regulation of hormone secretion GO:0046883 9.4 HTR1A CCKAR
17 regulation of serotonin secretion GO:0014062 9.32 HTR1A CRH
18 cholecystokinin signaling pathway GO:0038188 9.26 CCKBR CCKAR
19 serotonin receptor signaling pathway GO:0007210 9.13 HTR3A HTR2A HTR1A
20 response to pain GO:0048265 8.92 TSPO SLC6A2 CRH COMT
21 signal transduction GO:0007165 10.18 PTK7 HTR3A HTR2A HTR1A CRH CCKBR

Molecular functions related to Panic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter:sodium symporter activity GO:0005328 9.26 SLC6A4 SLC6A2
2 monoamine transmembrane transporter activity GO:0008504 9.16 SLC6A4 SLC6A2
3 cholecystokinin receptor activity GO:0004951 8.96 CCKBR CCKAR
4 serotonin binding GO:0051378 8.92 SLC6A4 HTR3A HTR2A HTR1A

Sources for Panic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....